Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Medtronic
Dow
Merck
Boehringer Ingelheim

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

SILVADENE Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Silvadene patents expire, and what generic alternatives are available?

Silvadene is a drug marketed by King Pharms Llc and is included in one NDA.

The generic ingredient in SILVADENE is silver sulfadiazine. There are twenty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the silver sulfadiazine profile page.

Drug patent expirations by year for SILVADENE
Drug Prices for SILVADENE

See drug prices for SILVADENE

Drug Sales Revenue Trends for SILVADENE

See drug sales revenues for SILVADENE

Pharmacology for SILVADENE
Synonyms for SILVADENE
(4-Amino-N-2-pyrimidinylbenzenesulfonamidato-NN,01)-silver
(4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver
[4-Amino-N-(2-pyrimidinyl-kN1)benzenesulfonamidato-kO]silver
22199-08-2
4-amino-N-(2-pyrimidinyl)benzenesulfonamide silver salr
4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
4-Amino-n-(2-pyrimidyl)benzene-sulfonamide monosilver salt
4-Amino-N-2-pyrimidinylbenzenesulfonamide Silver Complex
AB0011467
AC-3535
AC1L9ATF
AC1L9Q6O
AC1NUR63
AK323659
AKOS005111099
ARONIS23842
AS-13863
Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt
C10H9AgN4O2S
CAS-22199-08-2
CHEBI:9142
CHEMBL1382627
CPD001906773
D00433
DB05245
Dermazin
Dermazine
dermazinr
DSSTox_CID_28572
DSSTox_GSID_48646
DSSTox_RID_82844
DTXSID4048646
EINECS 244-834-5
Flamazine
Flammazine
FT-0630481
Geben
geber
I06-0145
I06-145
J-014582
KS-00000H21
MFCD00072101 (97%)
MolPort-003-986-619
N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt
N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt
NCGC00183137-01
NCGC00188438-01
NSC 625324
NSC625324
S0595
SAM002564255
SAM002699902
SC-17618
SCHEMBL15633
Silbertone
Sildaflo
Silvadene (TN)
silver (4-aminophenyl)sulfonyl-pyrimidin-2-yl-azanide
silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
Silver (I) sulfadiazine, 98%
silver (I) sulfadiazinr
silver sulfadiazinate
silver sulfadiazine
Silver sulfadiazine, 98%
Silver sulphadiazine
Silver, (4-amino-N-2-pyrimidinylbenzenesulfonamidato-NN,O1)-
Silver, [4-amino-N-(2-pyrimidinyl-kN1)benzenesulfonamidato-kO]-
silver;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide
silver(1+) ion 4-{[(pyrimidin-2-yl)azanidyl]sulfonyl}aniline
silver(1+) ion sulfadiazinate
silver(1+) sulfadiazinate
Silver(I) sulfadiazine
SSD
Sulfadiazin silber
Sulfadiazin, silbersalz
SULFADIAZINE SILVER
Sulfadiazine silver (JP17)
Sulfadiazine silver salt
Sulfadiazine, silver
Sulfadiazine, silver (USP)
Sulfadiazine, silver [USAN:USP]
Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt
SY105573
Thermazene
TL8001845
Tox21_112998
Tox21_113471
UNII-W46JY43EJR
W46JY43EJR
Paragraph IV (Patent) Challenges for SILVADENE
Tradename Dosage Ingredient NDA Submissiondate
SILVADENE CREAM;TOPICAL silver sulfadiazine 017381

US Patents and Regulatory Information for SILVADENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms Llc SILVADENE silver sulfadiazine CREAM;TOPICAL 017381-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKesson
Harvard Business School
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.